Scandion Oncology A/S Cash Flow Conversion Efficiency
Scandion Oncology A/S cash flow conversion efficiency. Based on the latest financial reports, Scandion Oncology A/S (SCOL) has a cash flow conversion efficiency ratio of -0.220x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.82 Million ≈ $-195.65K USD) by net assets (Skr8.27 Million ≈ $889.77K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scandion Oncology A/S (2017–2024)
Cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024. This chart illustrates how Scandion Oncology A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Scandion Oncology A/S for real-time trading data and today's change.
Scandion Oncology A/S Cash Flow Conversion Ratio Explained
Scandion Oncology A/S cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scandion Oncology A/S Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scandion Oncology A/S ranked by their cash flow conversion efficiency. Also see SCOL market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viaplay Group AB Series A
ST:VPLAY-A
|
0.037x |
|
Stora Enso Oyj ser. A
ST:STE-A
|
0.003x |
|
Kiliaro AB
ST:KILI
|
2.808x |
|
ECORUB AB B
F:7M8
|
-3.107x |
|
Frontier IP Group Plc
LSE:FIPP
|
-0.044x |
|
PowerHouse Energy Group Plc
LSE:PHE
|
-0.190x |
|
Boostheat
PA:ALBOO
|
-8.082x |
|
Headlam Group
LSE:HEAD
|
-0.182x |
Annual Cash Flow Conversion Efficiency for Scandion Oncology A/S (2017–2024)
The table below shows the annual cash flow conversion efficiency of Scandion Oncology A/S from 2017 to 2024. Review Scandion Oncology A/S (SCOL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr8.27 Million ≈ $889.77K |
Skr-27.52 Million ≈ $-2.96 Million |
-3.328x | -104.45% |
| 2023-12-31 | Skr31.12 Million ≈ $3.35 Million |
Skr-50.67 Million ≈ $-5.45 Million |
-1.628x | -64.88% |
| 2022-12-31 | Skr70.33 Million ≈ $7.57 Million |
Skr-69.44 Million ≈ $-7.47 Million |
-0.987x | -107.29% |
| 2021-12-31 | Skr104.54 Million ≈ $11.25 Million |
Skr-49.80 Million ≈ $-5.36 Million |
-0.476x | -325.45% |
| 2020-12-31 | Skr155.87 Million ≈ $16.77 Million |
Skr-17.45 Million ≈ $-1.88 Million |
-0.112x | +79.38% |
| 2019-12-31 | Skr18.34 Million ≈ $1.97 Million |
Skr-9.96 Million ≈ $-1.07 Million |
-0.543x | +48.59% |
| 2018-12-31 | Skr12.57 Million ≈ $1.35 Million |
Skr-13.28 Million ≈ $-1.43 Million |
-1.056x | -28.93% |
| 2017-12-31 | Skr1.45 Million ≈ $156.34K |
Skr-1.19 Million ≈ $-128.07K |
-0.819x | -- |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more